CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 297 enrolled
Drug / intervention
Alair System +1 moredevice
Likely dose
Not stated in record
Key inclusion· 6
  • Age 18–65 years
  • Asthma on maintenance therapy with both inhaled corticosteroid and long-acting beta-2 agonist
  • Pre-bronchodilator FEV1 ≥60% predicted
  • Airway hyperresponsiveness: PC20 <8 mg/mL on methacholine challenge
Key exclusion· 6
  • Post-bronchodilator FEV1 <65%
  • ≥3 hospitalizations for asthma exacerbations in prior year OR life-threatening asthma (prior intubation or ICU admission within 24 months)
  • >3 lower respiratory tract infections requiring antibiotics in past 12 months
  • ≥4 pulses of oral steroids for asthma in past 12 months

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00231114
NCT00231114N/ACompleted

Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)

Boston Scientific Corporation·interventional·Posted Oct 4, 2005·Updated Jul 27, 2017

In Brief

A clinical study evaluating Alair System for Asthma. Completed, enrolled 297 participants across 39 sites in 7 countries.

Detailed Summary

The objective of this randomized, double blind, sham-controlled study is to demonstrate the safety and effectiveness of the Alair System in a population of subjects with severe asthma who are still symptomatic despite being managed on conventional therapy of high doses of inhaled corticosteroids and long-acting β2-agonists. The primary efficacy endpoint will be the difference between Study groups in the change in Asthma Quality of Life Questionnaire (AQLQ) score from Baseline and the average score from the 6-, 9-, and 12-month follow-up visits. All other outcome measures assessed at 12 months post-treatment. This will be a multicenter, randomized, double-blind, sham-controlled study comparing the effects of treatment with the Alair System to conventional therapy of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA). A Bayesian adaptive approach to sample size selection is used with a randomization scheme of 2:1 (two Alair Group Subjects for every one Control Group Subject).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesAustralia, Brazil, Canada, Denmark, Netherlands, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 4, 2005
Enrollment StartSep 1, 2005
Primary CompletionAug 1, 2008
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.7 years ago

Interventions

Alair Systemdevice

Treatment of airways with the Alair System

Alair Systemdevice

Sham treatment of airways with the Alair System